Anne-Claire Hardy-Bessard

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m²) and the Currently Approved Dose (25 mg/m²) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA

Mario A. Eisenberger, Anne-Claire Hardy-Bessard, Choung‐Soo Kim et al. · Journal of Clinical Oncology · 2017 · 289 citations

Medicine, Oncology, Pharmacology +17

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

Aditya Bardia, Komal Jhaveri, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2024 · 140 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer

Andreas du Bois, Jørn Herrstedt, Anne-Claire Hardy-Bessard et al. · Journal of Clinical Oncology · 2010 · 105 citations · Full text

Medicine, Oncology, Pharmacology +15

Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer

Olivier Trédan, Mario Campone, Jacek Jassem et al. · Clinical Breast Cancer · 2014 · 59 citations

Medicine, Oncology, Pharmacology +14

Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database

Nicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou et al. · European Urology Oncology · 2018 · 31 citations

Medicine, Oncology, Urology +16